Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steve Dorman

Allergy & Immunology Jacksonville, FL Medical Doctor

NPI 1043519333 CMS profile 1391888

4123 University Blvd Ste B, Jacksonville, FL 32216

Open in the dashboard

General payments

$207,521

442 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$89,020 paid to institutions, not to them · program year 2025

Through program year 2025, Steve Dorman of Jacksonville, FL is reported in the CMS Open Payments database as having received $207,521 across 442 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $89,020 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $119,052 181
2024 General $71,206 141
2023 General $12,420 61
2022 General $4,186 33
2021 General $280 7
2020 General $32 2
2019 General $344 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steve Dorman
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Steve Dorman were reported at $119,052. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Steve Dorman Allergy & Immunology median Middle half National median
2019 $344 $594 $163–$1,512 $163
2020 $32 $426 $106–$1,233 $114
2021 $280 $638 $157–$1,708 $132
2022 $4,186 $790 $205–$1,961 $149
2023 $12,420 $852 $220–$2,147 $160
2024 $71,206 $865 $203–$2,267 $164
2025 $119,052 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $94,702 148 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $38,419 55 payments
  3. Novartis Pharmaceuticals Corporation $24,706 64 payments
  4. Ionis Pharmaceuticals, Inc. $24,267 32 payments
  5. BioCryst US Sales Co., LLC $9,307 51 payments
  6. Genentech, Inc. $5,839 9 payments
  7. Genentech USA, Inc. $4,965 13 payments
  8. Genzyme Corporation $2,031 7 payments
  9. Cycle Pharmaceuticals Inc $1,120 1 payment
  10. BioCryst Pharmaceuticals, Inc. $825 2 payments
  11. Other $1,340 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131,090 61 payments
  2. Consulting Fee $54,474 15 payments
  3. Travel and Lodging $12,315 77 payments
  4. Food and Beverage $9,524 286 payments
  5. Education $119 3 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $94,305 134 payments
  2. TAKHZYRO $24,339 34 payments
  3. DAWNZERA $24,242 31 payments
  4. Xolair Immunology $10,777 21 payments
  5. Orladeyo $2,914 49 payments
  6. NITYR $1,120 1 payment
  7. COSENTYX $672 1 payment
  8. XOLAIR Pulmonary/Respiratory Diseases $217 19 payments
  9. FASENRA $178 8 payments
  10. Xembify $176 16 payments
  11. Other $1,698 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,294

Median for Allergy/ Immunology: 449

Drug cost

$569,025

Median for Allergy/ Immunology: $169,700

Branded share of claims

33.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 58 $193,116
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 28 $83,548
Tezspire Tezepelumab-Ekko Brand 15 $78,353
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 17 $64,984
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 74 $54,798
Dupixent Pen Dupilumab Brand 11 $40,344
Breo Ellipta Fluticasone/Vilanterol Brand 57 $22,640
Symbicort Budesonide/Formoterol Fumarate Brand 19 $5,649
Ipratropium Bromide Generic 97 $3,770
Wixela Inhub Fluticasone Propion/Salmeterol Brand 22 $3,603

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$412,279

Of which drugs: $334,076

Medicare patients

326

Average age 73

Services billed

22,968

213 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 58%
Ischemic heart disease 29%
Diabetes 27%
Depression 26%
Chronic kidney disease 21%
Atrial fibrillation 20%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 11 7,185 $214,473

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $42,929
$42,929 — —
XOLAIR
  • Genentech USA, Inc. $4,927
  • Genentech, Inc. $131
  • Novartis Pharmaceuticals Corporation $129
$5,187 58 7,185
Orladeyo
  • BioCryst US Sales Co., LLC $219
$219 — —
TAKHZYRO
  • Takeda Pharmaceuticals U.S.A., Inc. $158
$158 — —
Xembify
  • Grifols USA, LLC $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

442 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record